Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daiki Murata

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Cancer Research Communications|July 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung CancerTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Translational Lung Cancer Research|June 19, 2025
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expressionHayato Kawachi, Tae Hata, Tadaaki Yamada, et al.
Clinical Lung Cancer|January 26, 2025
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort StudyTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Cancer Research and Treatment|November 1, 2024
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective StudyNaoya Nishioka, Tae Hata, Tadaaki Yamada, et al.
Translational Lung Cancer Research|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in JapanShiho Goda, Tadaaki Yamada, Kenji Morimoto, et al.
Lung Cancer (Amsterdam, Netherlands)|October 5, 2025
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective studyDaiki Murata, Koichi Azuma, Kenta Murotani, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Cancer Research Communications|July 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung CancerTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Translational Lung Cancer Research|June 19, 2025
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expressionHayato Kawachi, Tae Hata, Tadaaki Yamada, et al.
Clinical Lung Cancer|January 26, 2025
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort StudyTae Hata, Tadaaki Yamada, Yasuhiro Goto, et al.
Cancer Research and Treatment|November 1, 2024
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective StudyNaoya Nishioka, Tae Hata, Tadaaki Yamada, et al.
Translational Lung Cancer Research|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in JapanShiho Goda, Tadaaki Yamada, Kenji Morimoto, et al.
Lung Cancer (Amsterdam, Netherlands)|October 5, 2025
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective studyDaiki Murata, Koichi Azuma, Kenta Murotani, et al.
Pageof 8